<DOC>
	<DOC>NCT00709228</DOC>
	<brief_summary>To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) negative at treatment week 4 and week 24. To determine the proportion of patients (%) with sustained virological response at 24 weeks post follow up treatment.</brief_summary>
	<brief_title>Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)</brief_title>
	<detailed_description>Approximately 500 patients from about 100 sites to be identified as HCV LVL G1 patients</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Willingness to participate 18 years or older, either gender, any race Must have Hepatitic C Virus Low Viral Load [LCV LVL] (positive, but &lt;600,000 IU/mL on the assay used by the individual study site. Only Hepatitis C VirusRibonucleic acid/quantitative polymerase chain reaction [HCVRNA/qPCR] assays with results in IU/ml are acceptable) AND been diagnosed with Genotype 1 Subject considered suitable for treatment per local label Investigator considers suitable and subject consents to be treated Does not show negative polymerase chain reaction [PCR] at week 4 Pregnant women or those who plan to become pregnant or sexual partners of women who plan to become pregnant Subject does not qualify based on contraindication, special warning, special population, and/or pregnancy &amp; lactation section of the Summary of Product Characteristics [SmPC]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>